Poseida Sinks On Prostate Cancer CAR-T Clinical Hold

The Newly Public Company’s Stock Closed Down 30%

Poseida’s technologies are designed to deliver safer, more effective cell and gene therapies, but the first trial for its autologous PSMA-targeting CAR-T therapy was put on a clinical hold after a patient died.

stopping the Dominio effect
A Phase I trial of P-PSMA-101 was stopped after a prostate cancer patient died

Poseida Therapeutics, Inc. is built on technology platforms that it says can deliver safer and more effective cell and gene therapies, but the company saw its stock sink 30.3% to close at $9.06 on 18 August after revealing that the Phase I clinical trial for its chimeric antigen receptor T-cell (CAR-T) therapy P-PSMA-101 was put on a clinical hold following a metastatic castrate-resistant prostate cancer (mCRPC) patient’s death from liver failure.

San Diego-based Poseida said in a US Securities and Exchange Commission (SEC) filing after the stock market closed on 17...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D